ISG15 and neoplasm: In the subcutaneous tumors, the mice that received Lm-LLO-ISG15 demonstrated a significantly reduced tumor growth rate (Figure 5B and Figure S2I,J) and smaller final tumor mass (Figure 5C,D) compared to that of the control Lm.